Research Paper Volume 16, Issue 6 pp 5163—5183
Novel histone acetylation-related lncRNA signature for predicting prognosis and tumor microenvironment in esophageal carcinoma
Figure 10. Estimation of the HARlncRNA signature in immunotherapy response. (A) Expression of ICGs in different risk groups. (B) Differences of TIDE score between the high- and low-risk groups. (C–H) Correlation of risk score with immune checkpoints. *P < 0.05; **P < 0.01; ***P < 0.001.